Printer Friendly

ENHANCERS -- NEW CLASS OF ANTIBIOTICS -- TO TACKLE $1.5 BILLION MARKET

 VANCOUVER, British Columbia, June 30 /PRNewswire/ -- Micrologix Biotech Inc. announced that it has acquired worldwide exclusive rights to antimicrobial technology developed by CBDN (Canadian Bacterial Disease Network) researchers at the University of British Columbia. Using genetic engineering techniques, CBDN researchers have developed peptide molecules that possess potent antibacterial properties. This enabling technology allows these peptides, termed Enhancers, to behave like antibiotics or enhance the effectiveness of conventional antibiotics.
 When presented alone, Enhancers bind to a bacterium's cell wall and disintegrate the wall which leads to the destruction of the bacterium. If antibiotics are used in combination with the Enhancer Technology the disruption of the cell wall allows the antibiotic to penetrate the bacterium and cause cell death. This approach is particularly well suited for those bacteria which have built up a high resistance to antibiotics (i.e. those bacteria which have a cell wall which cannot be penetrated by the antibiotic).
 In North America alone, 2 million people acquire hospital-derived (nosocomial) infections at a cost of $1.5 billion annually. "Nosocomial infections are a major medical concern and increase health care costs because they lengthen hospital stays, can cause death and have a propensity to spread," according to Dr. Anthony Chow, head of Infectious Diseases at Vancouver General Hospital. "This technology represents a novel approach to better treat such infections and address the problem of antibiotic resistance."
 Micrologix is developing a family of therapeutics based on these peptides as direct killers of bacteria that cause human disease. By using the power of genetic engineering, Enhancer Technology will allow for the production of both broad-spectrum antibiotic compounds and specific compounds at a significantly lower cost than chemical synthesis methods currently available in the industry.
 Micrologix researchers can use this technology to design more potent compounds with optimal characteristics for human therapeutic use. Kevin Nephin, executive vice president of Micrologix, indicated that the company has a lead compound in development that has shown the ability to kill several of the most dangerous hospital derived bacterial infections.
 CBDN, one of the Networks of Centres of Excellence, is a national research consortium interested in all areas of bacterial diseases. Micrologix Biotech Inc. was founded in 1986 to develop novel therapeutics and diagnostics based on the expertise of its scientific advisory board in infectious diseases.
 Subject to VSE approval, a finder's fee of 50,000 shares is payable to Provincial Securities in connection with this acquisition.
 -0- 6/30/93
 /CONTACT: Kevin Nephin, executive VP of Micrologix Biotech, 800-665-1968; or Robert Hancock, scientific director of Canadian Bacterial Diseases Network, 604-822-4040/
 (MBI.)


CO: Micrologix Biotech Inc.; Canadian Bacterial Disease Network ST: British Columbia IN: MTC SU: PDT

JL-MF -- LA012 -- 7012 06/30/93 09:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1993
Words:450
Previous Article:FIDELITY NATIONAL FINANCIAL INC. ANNOUNCES PURCHASE OF CAPITOL OF TEXAS TITLE CO.
Next Article:INTERNATIONAL MOVIE GROUP REPORTS COMPLETION OF DEBT RESTRUCTURING
Topics:


Related Articles
ABBOTT INTRODUCES NEW MACROLIDE ANTIBIOTIC IN U.S.
ABBOTT LABORATORIES INTRODUCES NEW QUINOLONE ANTIBIOTIC
PathoGenesis Corp. Receives $1.5 Million Grant to Identify New Antibiotics For Lung Infections.
Galenica awarded patent for chemically modified immune enhancing agents.
Rib-X Pharmaceuticals Receives U.S. Patent for Technology Enabling Antibiotic Structure-Based Drug Design.
Rib-X Pharmaceuticals receives patent for bacteria technology.
The FDA:s antibiotic resistance: if bacteria are becoming increasingly resistant to current antibiotics, why is the FDA discouraging the development...
Imugene receptor mimic patent granted in United States.
Enanta Pharmaceuticals Achieves Milestone in Collaboration with Shionogi & Co., Ltd., as Phase 1 Studies Initiate in Japan on EP-013420, a...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters